TY - JOUR T1 - High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron JF - medRxiv DO - 10.1101/2021.12.20.21268130 SP - 2021.12.20.21268130 AU - Nigel Garrett AU - Asa Tapley AU - Jessica Andriesen AU - Ishen Seocharan AU - Leigh H. Fisher AU - Lisa Bunts AU - Nicole Espy AU - Carole L. Wallis AU - April Kaur Randhawa AU - Nzeera Ketter AU - Margaret Yacovone AU - Ameena Goga AU - Linda-Gail Bekker AU - Glenda E. Gray AU - Lawrence Corey Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/14/2021.12.20.21268130.abstract N2 - The early widespread dissemination of Omicron indicates the urgent need to better understand the transmission dynamics of this variant, including asymptomatic spread among immunocompetent and immunosuppressed populations. In early December 2021, the Ubuntu clinical trial, designed to evaluate efficacy of the mRNA-1273 vaccine (Moderna) among persons living with HIV (PLWH), began enrolling participants. Nasal swabs are routinely obtained at the initial vaccination visit, which requires participants to be clinically well to receive their initial jab. Of the initial 230 participants enrolled between December 2 and December 17, 2021, 71 (31%) were PCR positive for SARS-CoV-2: all of whom were subsequently confirmed by S gene dropout to be Omicron; 48% of the tested samples had cycle threshold (CT) values <25 and 18% less than 20, indicative of high titers of asymptomatic shedding. Asymptomatic carriage rates were similar in SARS-CoV-2 seropositive and seronegative persons (27% respectively). These data are in stark contrast to COVID-19 vaccine studies conducted pre-Omicron, where the SARS-CoV-2 PCR positivity rate at the first vaccination visit ranged from <1%-2.4%, including a cohort of over 1,200 PLWH largely enrolled in South Africa during the Beta outbreak. We also evaluated asymptomatic carriage in a sub study of the Sisonke vaccine trial conducted in South African health care workers, which indicated 2.6% asymptomatic carriage during the Beta and Delta outbreaks and subsequently rose to 16% in both PLWH and PHLWH during the Omicron period.These findings strongly suggest that Omicron has a much higher rate of asymptomatic carriage than other VOC and this high prevalence of asymptomatic infection is likely a major factor in the widespread, rapid dissemination of the variant globally, even among populations with high prior rates of SARS-COV-2 infection.Competing Interest StatementLC reports grant funding from the NIAID/NIH. All other authors have nothing to declareClinical TrialPACTR202105817814362Funding StatementFunding was provided by NIAID/NIH UM1 AI068614-14 (CoVPN LOC), UM1 AI068635 (CoVPN SDMC); 3UM1AI068618-15S1 (CoVPN LC). The Sisonke study was funded by the National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation (Grant number 21-V0001), and the Bill & Melinda Gates Foundation (grant number INV-030342). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the South African Health Products Regulatory Authority (SAHPRA); Human Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South Africa; and Human Research Ethics Committee, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs the trial is ongoing, access to patient-level data and supporting clinical documents with qualified external researchers may be available upon request and subject to review once the trial is complete. ER -